Bharat Immunologicals Fair Value
Bharat Immunologicals (BIBCL) average fair value is ₹23.03 across 4 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF), vs a current market price of ₹14.16 (+62.62%), fair value range ₹3.76–₹60.07. Browse BIBCL annual financials for revenue, profit, balance sheet and cash flow data.
Fair Value Analysis Export
BIBCL Fair Value vs Current Price — Valuation Summary
BIBCL average fair value, fair value range, price gap and valuation status across 4 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit Bharat Immunologicals share price today.
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Discounted Cash Flow (DCF)
BIBCL Fair Value Analysis — Data Sources & Coverage
Bharat Immunologicals financial data sources, valuation methods applied and sector benchmarks used. Read BIBCL dividend growth for the complete payout history and dividend yield track record.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
BIBCL vs Healthcare Sector Peers — P/E, P/B & Market Cap
Bharat Immunologicals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.